Press release: New scientific reports demonstrate the high accuracy of mariPOC COVID-19 tests in decentralized testing
Nasal sampling and EU RAT list
Press release: ArcDia launches a quick and automated COVID-19 antigen test with superior performance
Press release: Bruker to distribute ArcDia’s mariPOC® products for automated antigen POCT of COVID-19 and other infectious diseases in Central Europe
Press release: ArcDia Ltd’s automated coronavirus point-of-care test CE marked and available
Press Release: ArcDia Ltd reports a breakthrough in the development of an automated coronavirus point-of-care test
Press Release: ArcDia’s products would allow testing of all respiratory tract and COVID-19 patients in Finland
New mariPOC® publication: Evaluation of a Gastrointestinal Pathogen Panel Immunoassay in Stool Testing of Patients with Suspected Clostridioides (Clostridium) difficile Infection.
New mariPOC® publication: Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children.
ArcDia has entered into an exclusive license agreement with Xinhua Healthcare for the commercialisation of ArcDia’s mariPOC® technology in China
New research data shows that influenza antigen testing correlates best with the infectivity period
New test for Flu A
New mariPOC® Gastro test available
The diagnostics of group A streptococcus from pharyngeal swab samples by bacterial culture is challenged by a novel mariPOC point of care test.
The Evolution of Rapid POC Tests for Infectious Disease Diagnostics: An Exclusive SelectScience Interview
New press release
Mr. Vesa Kemppainen appointed as the new CEO
Mr. Vesa Kemppainen has been appointed as the CEO of ArcDia International Ltd as of October 7th 2019.
Dr. Aleksi Soini, co-founder of ArcDia, will continue to contribute to ArcDia as Senior Vice President of Business Development.